Research Article

Aortic Arch Calcification Is a Strong Predictor of the Severity of Coronary Artery Disease in Patients with Acute Coronary Syndrome

Xiaoteng Ma,1 Fangjie Hou,1,2 Jing Tian,3 Zhen Zhou,4 Yue Ma,1 Yujing Cheng,1 Yu Du,1 Hua Shen,1 Bin Hu,1 Zhijian Wang,1 Yuyang Liu,1 Yingxin Zhao,1 and Yujie Zhou1

1Department of Cardiology, 12th ward, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Beijing 100029, China
2Department of Cardiology, Qingdao Municipal Hospital, Qingdao 266000, China
3Department of Nuclear Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
4Department of Radiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China

Correspondence should be addressed to Yujie Zhou; azzyj12@163.com

Received 15 May 2019; Accepted 30 July 2019; Published 7 August 2019

Academic Editor: Kimimasa Tobita

Copyright © 2019 Xiaoteng Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The purpose of this study was to investigate the correlation of the extent of aortic arch calcification (AAC) detectable on chest X-rays with the severity of coronary artery disease (CAD) as evaluated by the SYNTAX score (SS) in patients with acute coronary syndrome (ACS).

Methods. A total of 1,418 patients (344 women; 59 ± 10 years) who underwent coronary angiography for ACS and were treated with coronary revascularization were included in the present study; chest X-rays were performed on admission. The AAC extent was divided into four grades (0–3). SS was calculated based on each patient's coronary angiographic findings. The relationship between the AAC extent and SS was assessed. Results. The AAC extent was positively correlated with SS (ρ = 0.639, P < 0.001). In the multivariate analysis, compared with grade 0, odds ratios (ORs) of AAC grades 1, 2, and 3 in predicting SS > 22 were 12.95 (95% CI, 7.85–21.36), 191.76 (95% CI, 103.17–356.43), and 527.81 (95% CI, 198.24–1405.28), respectively. Receiver operating characteristic curve analysis yielded a strong predictive ability of the AAC extent for SS > 22 (area under curve = 0.840, P < 0.001). Absence of AAC had a sensitivity, specificity, positive prognostic value, negative prognostic value, and accuracy of 46.7%, 95.9%, 94.1%, 56.4%, and 67.3%, respectively, for SS ≤ 22. AAC grades ≥ 2 had a sensitivity of 66.3%, specificity of 89.2%, positive prognostic value of 81.5%, negative prognostic value of 78.6%, and accuracy of 79.6% for the correct identification of SS > 22.

Conclusions. The extent of AAC detectable on chest X-rays might provide valuable information in predicting CAD severity in ACS patients.

1. Introduction

Patients with acute coronary syndrome (ACS) have a very high risk of cardiovascular (CV) morbidity and mortality, such that many of these patients undergo primary or elective coronary revascularization in combination with antithrombotic and lipid-lowering therapies to reduce elevated CV risk [1]. Among ACS patients managed with an early invasive strategy, baseline angiographic markers of disease burden, calcification, and lesion severity could provide important added independent predictive value for 30-day and 1-year ischemic outcomes [2]. The SYNERgy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) score (SS) is a valuable tool that can quantitatively estimate the severity of coronary lesions, and SS has been used to predict adverse CV events after coronary revascularization [3].

Arterial calcification has long been considered a complication of advanced atherosclerosis [4]. The aortic arch has been identified as the most vulnerable site for calcifications.
in the thoracic aorta [5]. Aortic arch calcification (AAC) is detectable on chest X-ray and accurately represents the magnitude of calcified change throughout the whole aorta [6]. Moreover, AAC can be detected readily and reproducibly using chest X-ray, which is a simple, inexpensive tool that is widely available for assessing hospitalized patients with chest pain. Several studies have reported that the presence of AAC could serve as an independent predictor of coronary artery calcium (CAC) presence, while the AAC extent was correlated with CAC scores [7, 8]. Furthermore, CAC has been demonstrated to provide incremental and independent power in predicting CAD severity [9, 10], suggesting that AAC might be a good predictor for CAD severity. Several recent studies have confirmed this assumption, indicating that AAC was associated with the severity of CAD, as evaluated by the number of diseased vessels or SS [11, 12]. However, these studies simply determined the presence of AAC without considering its extent and only included patients with non-ST-segment elevation ACS, excluding patients with ST-segment elevation myocardial infarction (MI).

In this cross-sectional study, we investigated the extent of AAC detectable in ACS patients from chest X-rays, determining if there was an association with the severity of CAD as evaluated by the SS.

2. Materials and Methods

2.1. Study Population. A total of 1,770 patients who underwent coronary angiography for ACS—and were treated with primary or elective coronary revascularization in our CV center between June 2016 and November 2017—were consecutively enrolled into a prospective registry. ACS was diagnosed according to the American College of Cardiology/American Heart Association guidelines [13, 14]. From the cohort, patients were excluded if they had prior coronary revascularization, were on chronic dialysis, or had been diagnosed with any known disease in the aorta, such as aortitis, aortic aneurysm, or dissection. Patients whose chest X-ray image quality was insufficient for interpretation were also excluded. Finally, 1,418 patients were included in the final analysis.

The present study was performed in accordance with the Helsinki Declaration of Human Rights and approved by the Medical Ethics Committee of Beijing Anzhen Hospital, Capital Medical University (Number: 2016034x). All patients provided written informed consent.

2.2. Measurements. Information on demographics, lifestyle, medical history, and daily medication use was collected with a detailed questionnaire. Weight, height, and blood pressure were measured following standardized procedures. All laboratory parameters were measured and analyzed immediately after collection from heparinized plasma samples at the central laboratory. Creatinine clearance (CrCl) was calculated using the Cockcroft and Gault formula [15]. Echocardiography was performed on admission and left ventricular ejection fraction was obtained using Simpson’s method from apical 2- and 4-chamber views according to the established American Society of Echocardiography protocols [16].

2.3. Assessment of Aortic Arch Calcification. All study patients received routine posterior-anterior chest X-rays (AXIOM Aristos MX, SIEMENS, Germany) or portable chest X-rays (MUX-200D, SHIMADZU, Japan) upon admission. AAC for each patient was assessed by two independent, experienced radiologists in a blinded fashion. If there was a dispute in interpretation, the opinion of another experienced radiologist was obtained and the final decision was made by consensus. The AAC extent was divided into four grades (0 to 3) (Figure 1(a)): grade 0, no visible calcification; grade 1, small spots of calcification or a single thin area of calcification of the aortic knob; grade 2, one or more areas of thick calcification; grade 3, circular calcification of the aortic knob [17].

2.4. SYNTAX Score. The SS was calculated based on each patient’s coronary angiographic findings, using 11 angiographic factors that take into account lesion location and characteristics. All coronary lesions that had a diameter stenosis ≥50% in vessels ≥1.5 mm were scored in accordance with the SS algorithm as previously described [18]. The SS was defined as low (≤22), intermediate (23–32), and high (≥33). Intermediate and high SSs are associated with more complex CAD and represent a bigger therapeutic challenge, as well as a potentially worse prognosis [19]. Two experienced interventional cardiologists in an independent angiographic core laboratory—who were unaware of the patients’ chest X-ray findings and clinical and laboratory parameters—indeliberately performed angiographic visual analysis for calculating the SS. When disagreement occurred, the opinion of a third observer was obtained and the final decision was made by consensus.

Based on the results from the original trial [19], the patients were stratified into two groups: SS ≤22 (low SS group) and SS >22 (intermediate-to-high SS group).

2.5. Statistical Analysis. Continuous variables were expressed as the mean ± standard deviation if consistent with a normal distribution; otherwise, they were reported as the median (0.25–0.75 percentiles). Categorical variables were presented as numbers (percentages). Differences in two continuous variables were analyzed by the Student’s t-test or the Mann-Whitney U test. Differences in categorical variables were tested using the chi-squared test or Fisher’s exact test, as appropriate. SSs among the four AAC grades were compared using analysis of variance (F test) and polynomial contrast tests. Spearman’s rank correlation coefficient (ρ) was calculated to evaluate the strength and direction of relationship between variables. Multivariate logistic regression analysis was performed to evaluate the independent contribution of the AAC extent to the risk of the intermediate-to-high SS. Effects of all variables on SS were calculated using univariate logistic regression analysis for each variable. Variables with a univariate significance level of ≤0.15 were entered into the multivariate logistic regression model. The linearity assumption between continuous variables and the logit in this model was assessed using the Box-Tidwell test. Fibrinogen and CrCl were found to be not linear as continuous variables with the logit and were therefore transformed into ordinal variables according to the quartiles of fibrinogen.
and generally accepted definition of chronic kidney disease (CKD) stages [20], respectively. All potential explanatory variables included in the multivariable analyses were subjected to collinearity analysis with a correlation matrix. The Hosmer–Lemeshow goodness-of-fit test was used to assess the fit of the logistic model. Odds ratios (ORs) and their 95% confidence intervals (CIs) were calculated. The predictive ability of the AAC extent for SS was evaluated. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of the test were calculated. All statistical tests were two-tailed, and a P value < 0.05 was considered to be statistically significant. Statistical analysis was performed using the IBM SPSS software (IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp.).

3. Results

A total of 1,418 patients were included in the present study. The study patients had a mean age of 59 ± 10 years and 24.3% (n = 344) of them were female. The mean SS value of the study population was 22 ± 11. The intraclass correlation efficient was 0.86 (P < 0.001) for the two interventional cardiologists who independently calculated SS. Within the cohort, 597 patients were allocated to the intermediate-to-high SS group, while 821 were allocated to the low SS group. The baseline characteristics, including the AAC extent, for all the patients based on SS are shown in Table 1. Patients with intermediate-to-high SS were older and had higher incidence of diabetes, prior MI, and peripheral vascular diseases than patients with low SS. Although there were no differences in hypertension between the two groups, patients in the intermediate-to-high SS group had a lower level of diastolic blood pressure. More patients developed acute MI in the intermediate-to-high SS group than in the low SS group.

Of all patients, 407 (28.7%), 524 (37.0%), 390 (27.5%), and 97 (6.8%) had AAC grades of 0, 1, 2, and 3, respectively (Figure 1(b)). Good interobserver agreement of the AAC extent was noted, with weighted k statistics of 0.81 (95% CI 0.73–0.89). Mean Ss were 13 ± 7, 21 ± 9, 29 ± 9, and 36 ± 13 in patients with AAC grades 0, 1, 2, and 3, respectively (P < 0.001). There was a linear trend between the four AAC grades and Ss (P < 0.001), and there was a significant difference in Ss across all four AAC grades: AAC grade 0 versus grade 1 (P < 0.001), 2 (P < 0.001), or 3 (P < 0.001); grade 1 versus grade 2 (P < 0.001) or 3 (P < 0.001); and grade 2 versus grade 3 (P < 0.001). The distribution of mean SS across the four AAC grades is shown in Figure 2. The AAC extent was significantly and positively correlated with SS (Rs = 0.475, P < 0.001) and heavy coronary calcification (Rs = 0.475, P < 0.001) (Table 2).

In the univariate analysis, compared to AAC grade 0, AAC grade 1 (OR 8.00, 95% CI 5.10–12.56), AAC grade 2 (OR 65.51, 95% CI 40.43–106.16), and AAC grade 3 (OR 98.21, 95% CI 47.96–201.08) were all the predictors of SS > 22. In the multivariate logistic regression analysis, compared to AAC grade 0, ORs of AAC grades 1, 2, and 3 in predicting SS > 22 were 12.95 (95% CI 7.85–21.36), 191.76 (95% CI 103.17–356.43), and 527.81 (95% CI 198.24–1405.28), respectively (Table 3).

Receiver operating characteristic curve analysis yielded a strong predictive ability of the AAC extent for SS > 22 (Figure 3, AUC = 0.840, 95% CI 0.819–0.861, P < 0.001).

Absence of AAC had a sensitivity, specificity, PPV, NPV, and accuracy of 46.7%, 95.9%, 94.1%, 56.4%, and 67.3%, respectively, for SS ≤ 22 (Table 4). An AAC grade of ≥ 2 predicted SS > 22 with a sensitivity, specificity, PPV, NPV, and accuracy of 66.3%, 89.2%, 81.5%, 78.6%, and 79.6%, respectively (Table 4). An AAC grade of 3 had a sensitivity, specificity, PPV, NPV, and accuracy of 13.5%, 98.4%, 86.0%, 61.3%, and 62.9%, respectively, for SS > 22 (Table 4). An AAC grade of 3 had a sensitivity of 24.0%, specificity of 97.1%, NPV of 63.4%, NPV of 85.8%, and accuracy of 83.4% for predicting a SS ≥ 33 (Table 4).

4. Discussion

To our knowledge, this is the first study to demonstrate a significant correlation of the extent of AAC detectable on a chest X-ray with the severity of CAD as evaluated by the SS in ACS patients. The predictive ability of absence of AAC was high for SS ≤ 22, while AAC grades 2 and 3 strongly predicted SS > 22.
| Variable                                      | All Patients | Low SS (N = 821) | Intermediate-to-high SS (N = 597) | P value |
|-----------------------------------------------|--------------|------------------|----------------------------------|---------|
| **N = 1,418**                                |              |                  |                                  |         |
| **Female gender, n (%)**                     | 344 (24.3)   | 203 (24.7)       | 141 (23.6)                       | 0.503   |
| **Age (years)**                              | 59±10        | 58±10            | 61±11                            | <0.001  |
| **Height (m)**                               | 1.69 (1.63–1.73) | 1.69 (1.63–1.73) | 1.68 (1.62–1.73)                | 0.269   |
| **Weight (kg)**                              | 73±12        | 73±12            | 72±12                            | 0.427   |
| **BMI (kg/m²)**                              | 25.7±3.3     | 25.7±3.3         | 25.7±3.3                        | 0.834   |
| **Family history of CHD, n (%)**             | 428 (30.2)   | 244 (29.7)       | 184 (30.8)                       | 0.766   |
| **Arterial hypertension, n (%)**             | 904 (63.8)   | 513 (62.5)       | 391 (65.5)                       | 0.248   |
| **Diabetes, n (%)**                          | 542 (38.2)   | 260 (31.7)       | 284 (48.1)                       | 0.088   |
| **Dyslipidemia, n (%)**                      | 1120 (79.0)  | 636 (77.5)       | 484 (81.1)                       | 0.088   |
| **History of MI, n (%)**                     | 148 (10.4)   | 56 (6.8)         | 92 (15.4)                        | <0.001  |
| **History of CA, n (%)**                     | 90 (6.3)     | 44 (5.4)         | 46 (7.7)                         | <0.001  |
| **Known PVD, n (%)**                         | 122 (8.6)    | 31 (3.8)         | 91 (15.2)                        | <0.001  |
| **COPD, n (%)**                              | 18 (1.3)     | 12 (1.5)         | 6 (1.0)                          | 0.461   |
| **Smoking**                                  |              |                  |                                  | 0.012   |
| **Never smokers, n (%)**                     | 592 (41.7)   | 339 (41.3)       | 253 (42.4)                       |         |
| **Former smokers, n (%)**                   | 158 (11.1)   | 76 (9.3)         | 82 (13.7)                        |         |
| **Current smokers, n (%)**                  | 668 (47.1)   | 406 (49.5)       | 262 (43.9)                       |         |
| **ACS types**                                |              |                  |                                  | 0.002   |
| **UA, n (%)**                                | 980 (69.1)   | 595 (72.5)       | 385 (64.5)                       |         |
| **NSTEMI, n (%)**                            | 204 (14.4)   | 100 (12.2)       | 104 (17.4)                       |         |
| **STEMI, n (%)**                             | 234 (16.5)   | 126 (15.3)       | 108 (18.1)                       |         |
| **Medical measurements (on admission)**      |              |                  |                                  |         |
| **SBP (mmHg)**                               | 130±17       | 130±17           | 130±17                           | 0.999   |
| **DBP (mmHg)**                               | 76±11        | 77±11            | 75±11                            | 0.021   |
| **Laboratory measurements (on admission)**   |              |                  |                                  |         |
| **CK-MB (ng/ml)**                            | 1.3 (0.9–1.9)| 1.2 (0.9–1.9)    | 1.4 (0.9–2.0)                    | 0.015   |
| **cTnI (ng/ml)**                             | 0 (0–0.02)   | 0 (0–0.01)       | 0.01 (0–0.04)                    | <0.001  |
| **BNP (pg/ml)**                              | 36 (22–87)   | 33 (20–67)       | 43 (23–108)                      | <0.001  |
| **WBC count (10⁹/L)**                        | 6.43 (5.38–7.67) | 6.41 (5.42–7.68) | 6.47 (5.33–7.67)                | 0.651   |
| **Fibrinogen (g/L)**                         | 3.22 (2.80–3.68) | 3.16 (2.77–3.55) | 3.31 (2.92–3.82)                | <0.001  |
| **CRP (mg/L)**                               | 1.37 (0.55–4.10) | 1.23 (0.51–3.43) | 1.67 (0.63–5.64)                | <0.001  |
| **Laboratory measurements (fasting state)**  |              |                  |                                  |         |
| **TC (mmol/L)**                              | 4.18±1.02    | 4.18±1.01        | 4.18±1.02                        | 0.885   |
| **LDL-C (mmol/L)**                           | 2.49±0.83    | 2.46±0.83        | 2.53±0.83                       | 0.121   |
| **HDL-C (mmol/L)**                           | 1.00 (0.87–1.17) | 1.02 (0.87–1.18) | 0.97 (0.86–1.16)                | 0.003   |
| **TG (mmol/L)**                              | 1.43 (1.03–2.10) | 1.51 (1.05–2.13) | 1.37 (1.00–1.98)                | 0.012   |
| **FPG (mmol/L)**                             | 5.13 (5.66–6.99) | 5.49 (5.05–6.64) | 5.99 (5.26–7.45)                | <0.001  |
| **HbA1c (%)**                                | 5.9 (5.5–6.9) | 5.8 (5.5–6.6)    | 6.2 (5.6–7.4)                    | <0.001  |
| **CrCl (ml/min)**                            | 102±31       | 104±32           | 98±28                            | <0.001  |
| **LVeF (%)**                                 | 65 (60–68)   | 65 (60–69)       | 64 (60–68)                       | <0.001  |
| **Medications use (before admission)**       |              |                  |                                  |         |
| **Antiplatelet drugs, n (%)**                | 982 (69.3)   | 559 (68.1)       | 423 (70.9)                       | 0.322   |
| **HMG-CoA inhibitors, n (%)**                | 958 (67.6)   | 545 (66.4)       | 413 (69.2)                       | 0.326   |
| **ACE inhibitors/ARBs, n (%)**               | 350 (24.7)   | 198 (24.1)       | 152 (25.5)                       | 0.587   |
| **Beta-blockers, n (%)**                     | 517 (36.5)   | 270 (32.9)       | 247 (41.4)                       | 0.002   |
| **CCBs, n (%)**                              | 467 (32.9)   | 248 (30.2)       | 219 (36.7)                       | 0.008   |
| **Insulin, n (%)**                           | 202 (14.2)   | 76 (9.3)         | 126 (21.1)                       | <0.001  |
| **Sulfonyl Urea, n (%)**                     | 122 (8.6)    | 57 (6.9)         | 65 (10.9)                        | 0.013   |
| **Biguanides, n (%)**                        | 136 (9.6)    | 72 (8.8)         | 64 (10.7)                        | 0.276   |
| **Alpha-glucosidase inhibitors, n (%)**      | 98 (6.9)     | 44 (5.4)         | 54 (9.0)                         | 0.006   |
**Table 1:** Continued.

| Variable                                                                 | All Patients (N = 1,418) | Low SS (N = 821) | Intermediate-to-high SS (N = 597) | P value |
|--------------------------------------------------------------------------|--------------------------|------------------|----------------------------------|---------|
| **Angiographic characteristics**                                          |                          |                  |                                  |         |
| Left-main disease, n (%)                                                 | 116 (8.2)                | 18 (2.2)         | 98 (16.4)                        | <0.001  |
| Three-vessel disease, n (%)                                               | 786 (55.4)               | 294 (35.8)       | 492 (82.4)                       | <0.001  |
| Proximal LAD stenosis, n (%)                                              | 780 (55.0)               | 321 (39.1)       | 459 (76.9)                       | <0.001  |
| Trifurcation or bifurcation lesions, n (%)                               | 1094 (77.2)              | 554 (67.5)       | 540 (90.5)                       | <0.001  |
| Total occlusions, n (%)                                                   | 390 (27.5)               | 130 (15.8)       | 260 (43.6)                       | <0.001  |
| Heavy calcification lesions, n (%)                                       | 432 (30.5)               | 116 (14.1)       | 316 (52.9)                       | <0.001  |
| Lesions length >20mm, n (%)                                              | 750 (52.9)               | 323 (39.3)       | 427 (71.5)                       | <0.001  |
| **AAC grades**                                                           |                          |                  |                                  |         |
| Grade 0, n (%)                                                           | 407 (28.7)               | 383 (46.7)       | 24 (4.0)                         |         |
| Grade 1, n (%)                                                           | 524 (37.0)               | 349 (42.5)       | 175 (29.3)                       |         |
| Grade 2, n (%)                                                           | 390 (27.5)               | 76 (9.3)         | 314 (52.6)                       |         |
| Grade 3, n (%)                                                           | 97 (6.8)                 | 13 (1.6)         | 84 (14.1)                        |         |

SS: SYNTAX score; BMI: body mass index; CHD: coronary heart disease; CA: cerebrovascular accident; PVD: peripheral vascular disease; COPD: chronic obstructive pulmonary disease; MI: myocardial infarction; UA: unstable angina; NSTEMI: non-ST-segment elevation myocardial infarction; STEMI: ST-segment elevation myocardial infarction; SBP: systolic blood pressure; DBP: diastolic blood pressure; CK-MB: creatine kinase isoenzyme MB; cTnI: cardiac troponin I; BNP: brain natriuretic peptide; WBC: white blood cell; CRP: C-reactive protein; TC: total cholesterol; LDL-C: low-density lipoprotein-cholesterol; HDL-C: high-density lipoprotein-cholesterol; TG: triglyceride; HbA1c: glycated haemoglobin A1c; CrCl: creatinine clearance; LVEF: left ventricular ejection fraction; ACE: angiotensin converting enzyme; ARBs: angiotensin II receptor blockers; CCBs: calcium channel blockers; LAD: left anterior descending; AAC: aortic arch calcification.

**Table 2:** Correlation analysis between AAC, heavy coronary calcification, and SS.

| AAC grades and SS | Coronary calcification and SS | Coronary calcification and AAC grades |
|-------------------|-------------------------------|--------------------------------------|
| ρ                 | 0.639                         | 0.459                                | 0.475                                |
| P value           | <0.001                        | <0.001                               | <0.001                               |

Abbreviations: see Table 1.

**Table 3:** The predictive value of AAC grades for intermediate–high SS.

| Variable | Univariate | Multivariate* |
|----------|------------|---------------|
|          | OR, 95% CI | P value       | OR, 95% CI | P value |
| AAC grade 0 | Reference  | Reference     |            |         |
| AAC grade 1 | 8.00, 5.10–12.56 | <0.001 | 12.95, 7.85–21.36 | <0.001 |
| AAC grade 2 | 65.51, 40.43–106.16 | <0.001 | 191.76, 103.17–356.43 | <0.001 |
| AAC grade 3 | 98.21, 47.96–201.08 | <0.001 | 527.81, 198.24–1405.28 | <0.001 |

*Other variables included in multivariable analysis were age, diabetes, dyslipidemia, history of MI, history of CA, known PVD, smoking, ACS types, DBP, CK-MB, cTnI, fibrinogen categories, CRP, LDL-C, HDL-C, TG, FPG, HbA1c, CKD stages, LVEF, beta-blockers, CCBs, insulin, sulfonyl urea, and alpha-glucosidase inhibitors.

OR indicates odds ratio; for other abbreviations, see Table 1.

**Table 4:** Predictive ability of AAC grades for SS.

| Predictor (AAC grades) | Outcome (SS) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Accuracy (%) |
|------------------------|--------------|-----------------|-----------------|---------|---------|-------------|
| Grade = 0              | ≤ 22         | 46.7            | 95.9            | 94.1    | 56.4    | 67.3        |
| Grade ≥ 2              | > 22         | 66.3            | 89.2            | 81.5    | 78.6    | 79.6        |
| Grade = 3              | > 22         | 13.5            | 98.4            | 86.0    | 61.3    | 62.9        |
| Grade ≥ 3              | ≥ 33         | 24.0            | 97.1            | 63.4    | 85.8    | 84.3        |

AAC: aortic arch calcification; SS: SYNTAX score; PPV: positive predictive value; NPV: negative predictive value.
presence was associated with systolic and diastolic blood pressure, while also having a borderline association with total serum cholesterol [25]. In the Reykjavik study, AAC presence was independently associated with age, nonfasting plasma glucose, drug treatment for diabetes, blood pressure, use of antihypertensive agents, the amount of smoking, and serum cholesterol levels [26]. Iribarren et al. found that AAC was independently correlated with older age, current smoking, hypertension, and elevated total cholesterol levels [27]. Yamada et al. revealed that CKD in combination with diabetes—as well as hypertension in combination with CKD—strongly affected the risk of arterial calcification, especially at the aortic arch [28]. Symeonidis et al. categorized the AAC extent into four grades according to the amount, profile, and area of calcium on the aortic arch, revealing that the extent of AAC was significantly associated with older age, diabetes, hypertension, and dyslipidemia [17]. Similarly, Hashimoto et al. demonstrated that diabetes and renal dysfunction were significantly associated with increasing AAC grade [6]. The present study is consistent with these previous reports, finding a significant correlation between increasing AAC grade and traditional CV risk factors, such as older age, hypertension, diabetes, and CKD. Simultaneously, this study also found that patients with a higher AAC grade had a higher frequency of CV risk factors. In fact, there was heavier atherosclerotic plaque burden in CHD patients [29], which was concomitant with increased CV risk factors. Moreover, a number of angiographic and postmortem studies strongly support the notion that plaque burden severity significantly correlates with plaque instability and rupture [30].

In our study, we found a significant association between AAC and severe coronary calcification as defined by the SS algorithm. Several previous studies strongly and consistently support a significant, positive association between AAC on chest X-rays and CAC that is detected by computed tomography (CT) [7, 8]. Bannas et al. evaluated the association between AAC on chest X-rays and CAC scores that were determined by CT, where the AAC extent was divided into the same four grades (0–3) as the present study. Among 128 patients, the AAC extent was positively associated with CAC scores, while a cut-off between AAC grades 0–2 and 3 had a sensitivity of 38.6%, specificity of 96.4%, PPV of 85.0%, NPV of 75.0%, and accuracy of 76.6% for correctly identifying high-risk CAC scores (> 400 Au). Adar et al. also investigated the association between AAC on chest X-rays and CAC that was detected by CT, where AAC was graded according to the same algorithm as this study. Among 248 patients, AAC was a strong and independent predictor of CAC, and an AAC grade of ≥2 (sensitivity 68%, specificity 98%, PPV 75%, NPV 97%, and accuracy 95%) or 3 (sensitivity 45%, specificity 99%, PPV 83%, NPV 95%, and accuracy 94%) had strong predictive power for high-risk CAC scores (≥ 400 Au), while absence of AAC (sensitivity 90%, specificity 84%, PPV 96%, NPV 69%, and accuracy 89%) had strong predictive performance for low-risk CAC scores (< 100 Au). A recent genetic association study demonstrated that one specific single-nucleotide polymorphism (rs2026458) that was associated with CAC increased the risk of calcification in the aortic arch (β = 0.32, 95% CI 0.10–0.54, P = 0.004), demonstrating an internal correlation of CAC with AAC at
the molecular level [31]. Previous studies have indicated that CAC detected by CT is associated with the presence and amount of coronary atherosclerosis, including the amount of noncalcified plaque, while other studies have revealed that CAC could provide incremental and independent power in predicting CAD severity [8, 9]. These associations may suggest a correlation of the AAC extent with CAD severity.

Currently, there is limited data regarding the association between AAC and CAD severity in ACS patients [11, 12]. Yun et al. evaluated the association between AAC and CAD severity in patients with unstable angina, where, among 178 consecutive patients, they demonstrated that AAC prevalence increased in proportion to CAD severity. However, this study did not consider the AAC extent and only used the number of diseased vessels to represent CAD severity. Korkmaz et al. evaluated the association between AAC and the severity of CAD as evaluated by SS in non-ST-segment elevation ACS patients, where, among 135 consecutive patients, AAC (95% CI 1.7–6.9, \( P = 0.002 \)) was an independent determinant of SS in the linear regression analysis. However, this study did not consider the AAC extent and only had a small sample size.

At present, no data are available on the use of the AAC extent for the prediction of SS. In the present study, we found that an AAC grade of \( \geq 2 \) (sensitivity 66.3%, specificity 89.2%, PPV 81.5%, NPV 78.6%, and accuracy 79.6%) or 3 (sensitivity 13.5%, specificity 98.4%, PPV 86.0%, NPV 61.3%, and accuracy 62.9%) had a high predictive power for SS \( > 22 \). Moreover, we found a strong predictive performance of absence of AAC for SS \( 
\leq 22 \) (sensitivity 46.7% specificity 95.9%, PPV, 94.1%, NPV 56.4%, and accuracy 67.3%). The extremely high specificity in our study population seems to advocate the AAC extent for the screening of SS \( \leq 22 \) or \( > 22 \) patients with ACS, where a high specificity is desired, even with a trade-off for sensitivity.

There are several limitations to this study. First, using chest X-rays to assess the AAC extent is not a quantitative method and the true calcium deposition in the aortic arch could have been underestimated. Second, positional change on the chest X-ray could potentially alter the appearance of AAC and influence the measured value of AAC thickness. Third, the calcification detectable on a chest X-ray is a composite of both intimal and medial calcifications, which are two pathophysiologically separate processes [32]. However, a chest X-ray does allow for accurate distinction between intimal and medial calcifications. The differences in the proportion of intimal and medial calcifications in the aortic arch may result in different relations with coronary atherosclerotic lesions. Finally, although this study demonstrated a close relationship between the extent of AAC detectable on a chest X-ray and the severity of CAD as evaluated by SS in ACS patients, there was a lack of prognostic information of AAC for future adverse CV events.

5. Conclusions

Our study demonstrates that the AAC extent is positively associated with the severity of CAD as evaluated by SS in ACS patients. Our data strongly suggest that the AAC extent, as assessed by a simplified approach by chest X-ray, might provide complementary and valuable information in predicting CAD severity for ACS patients.

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.

**Conflicts of Interest**

The authors have no conflicts of interest to declare.

**Authors’ Contributions**

Xiaoteng Ma and Fangjie Hou contributed equally to this paper.

**Acknowledgments**

This work was supported by grants from National Key Research and Development Program of China (2017YFC0908800), Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20150601) and Mission Plan (SML20180601), and Beijing Municipal Health Commission—“Project of Science and Technology Innovation Center” (PXM2019_026272_000006) (PXM2019_026272_000005). We thank LetPub (www.letpub .com) for its linguistic assistance during the revision of this manuscript.

**References**

[1] S. Windecker, P. Kolh, F. Alfonso et al., “2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of percutaneous cardiovascular interventions (EAPCI),” *Russian Journal of Cardiology*, vol. 35, pp. 2541–2619, 2015.

[2] A. J. Lansky, K. Goto, E. Cristea et al., “Clinical and angiographic predictors of short- and long-term ischemic events in acute coronary syndromes,” *Circulation: Cardiovascular Interventions*, vol. 3, no. 4, pp. 308–316, 2010.

[3] F. J. Neumann, M. Sousa-Uva, A. Ahlsson et al., “ESC/EACTS Guidelines on myocardial revascularization,” *European Heart Journal*, vol. 40, pp. 87–165, 2019.

[4] H. Kälsh, N. Lehmann, S. Moebus et al., “Aortic calcification onset and progression: association with the development of coronary atherosclerosis,” *Journal of the American Heart Association*, vol. 6, no. 4, Article ID e005093, 2017.

[5] A. Diken, A. Yalçınkaya, and S. Özyalçın, “Distribution of thoracic aortic calcifications in patients undergoing coronary artery bypass grafting,” *AORTA*, vol. 05, no. 05, pp. 132–138, 2018.

[6] H. Hashimoto, K. Iijiima, M. Hashimoto et al., “Validity and usefulness of aortic arch calcification in chest X-ray,” *Journal of Atherosclerosis and Thrombosis*, vol. 16, no. 3, pp. 256–264, 2009.

[7] P. Bannas, C. Jung, P. Blanke et al., “Severe aortic arch calcification depicted on chest radiography strongly suggests coronary
artery calcification,” *European Radiology*, vol. 23, no. 10, pp. 2652–2657, 2013.

[8] A. Adar, H. Erkan, T. Gokdeniz, A. Karadeniz, I. G. Cavusoglu, and O. Onalan, “Aortic arch calcification is strongly associated with coronary artery calcification,” *Vasa*, vol. 44, no. 2, pp. 106–114, 2015.

[9] P. Greenland, R. O. Bonow, B. H. Brundage et al., “ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of atherosclerosis imaging and prevention and the society of cardiovascular computed tomography,” *Journal of the American College of Cardiology*, vol. 49, no. 3, pp. 378–402, 2007.

[10] M. J. Budoff, G. A. Diamond, P. Raggi et al., “Continuous probabilistic prediction of angiographically significant coronary artery disease using electron beam tomography,” *Circulation*, vol. 105, no. 15, pp. 1791–1796, 2002.

[11] K. H. Yun, M. H. Jeong, S. K. Oh et al., “Clinical significance of aortic knob width and calcification in unstable angina,” *Circulation Journal*, vol. 70, no. 10, pp. 1280–1283, 2006.

[12] L. Korkmaz, A. Adar, A. Ata Korkmaz et al., “Aortic knob calcification and coronary artery lesion complexity in non-ST-segment elevation acute coronary syndrome patients,” *Turk Kardiyol Dern Ars*, vol. 40, pp. 606–611, 2012.

[13] E. A. Amsterdam, N. K. Wenger, R. G. Brindis et al., “2014 AHA/ACC guideline for the management of patients with Non-ST-Elevation acute coronary syndromes: Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” *Journal of the American College of Cardiology*, vol. 64, no. 24, pp. 2645–2687, 2014.

[14] G. N. Levine, E. R. Bates, J. C. Blankenship et al., “2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American college of cardiology/American Heart Association task force on clinical practice guidelines and the society for cardiovascular angiography and interventions,” *Circulation*, vol. 133, no. 11, pp. 1135–1147, 2016.

[15] D. W. Cockcroft and M. H. Gault, “Prediction of creatinine clearance from serum creatinine,” *Nephron*, vol. 16, no. 1, pp. 31–41, 1976.

[16] R. M. Lang, M. Bierig, R. B. Devereux et al., “Recommendations for chamber quantification: a report from the American Society of Echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the european association of echocardiography, a branch of the European Society of Cardiology,” *Journal of the American Society of Echocardiography*, vol. 18, no. 12, pp. 1440–1463, 2005.

[17] G. Symeonidis, N. Papanas, I. Giannakis et al., “Gravity of aortic arch calcification as evaluated in adult Greek patients,” *International Angiology*, vol. 21, no. 3, pp. 233–236, 2002.

[18] G. Sianos, M. A. Morel, A. P. Kappetein et al., “The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease,” *EuroIntervention*, vol. 1, pp. 219–227, 2005.

[19] P. W. Serruys, M.-C. Morice, A. P. Kappetein et al., “Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease,” *The New England Journal of Medicine*, vol. 360, no. 10, pp. 961–972, 2009.

[20] P. E. Stevens and A. Levin, “Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline,” *Annals of Internal Medicine*, vol. 158, no. 11, pp. 825–830, 2013.

[21] S. Garg, G. Sarno, P.W. Serruys et al., “Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a study of the STRATEGY (single high-dose bolus tirofiban and sirolimus-eluting stent versus abciximab and bare-metal stent in acute myocardial infarction) and MULTISTRATEGY (multicenter evaluation of single high-dose bolus tirofiban versus abciximab with sirolimus-eluting stent or bare-metal stent in acute myocardial infarction study) trials,” *JACC: Cardiovascular Interventions*, vol. 4, pp. 66–75, 2011.

[22] A. Caixeta, P. Généreux, T. Palmerini et al., “Prognostic utility of the SYNTAX score in patients with single versus multivessel disease undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy Y [ACUITY] trial),” *American Journal of Cardiology*, vol. 113, no. 2, pp. 203–210, 2014.

[23] T. Palmerini, P. Généreux, A. Caixeta et al., “Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (acute catheterization and urgent intervention triage strategy Y) trial,” *Journal of the American College of Cardiology*, vol. 57, no. 24, pp. 2389–2397, 2011.

[24] D. Bos, M. J. Leening, M. Kavousi et al., “Comparison of atherosclerotic calcification in major vessel beds on the risk of all-cause and cause-specific mortality,” *Circulation: Cardiovascular Imaging*, vol. 8, no. 12, Article ID 0003843, 2015.

[25] J. C. Witteman, W. B. Kannel, P. A. Wolf et al., “Aortic calcified plaques and cardiovascular disease (the Framingham study),” *American Journal of Cardiology*, vol. 66, no. 15, pp. 1060–1064, 1990.

[26] R. Danielsen, H. Sigvaldason, G. Thorgerisson, and N. Sigfusson, “Prevalence of aortic calcification as an atherosclerotic manifestation in women: The Reykjavik study,” *Journal of Clinical Epidemiology*, vol. 49, no. 3, pp. 383–387, 1996.

[27] C. Iribarren, S. Sidney, B. Sternfeld, and W. S. Browner, “Calcification of the aortic arch: risk factors and association with coronary heart disease, stroke, and peripheral vascular disease,” *Journal of the American Medical Association*, vol. 283, no. 21, pp. 2810–2815, 2000.

[28] S. Yamada, M. Oshima, Y. Watanabe, and H. Miyake, “Arterial calcification of the aortic arch: risk factors and association with coronary artery calcification,” *Calcified Tissue International*, vol. 95, no. 3, pp. 267–274, 2014.

[29] H. Kaneda, T. Kataoka, J. Ako, Y. Honda, P. G. Yock, and P. J. Fitzgerald, “Coronary risk factors and coronary atheroma burden at severely narrowing segments,” *International Journal of Cardiology*, vol. 124, no. 1, pp. 124–126, 2008.
[30] T. J. Ford, C. Berry, B. De Bruyne et al., “Physiological predictors of acute coronary syndromes,” JACC: Cardiovascular Interventions, vol. 10, no. 24, pp. 2539–2547, 2017.

[31] Y. Zhang, L. Wang, Z. Zhang et al., “Shared and discrepant susceptibility for carotid artery and aortic arch calcification: A genetic association study,” Atherosclerosis, vol. 241, no. 2, pp. 371–375, 2015.

[32] D. Zhu, N. C. Mackenzie, C. Farquharson, and V. E. Macrae, “Mechanisms and clinical consequences of vascular calcification,” Front Endocrinol (Lausanne), vol. 3, no. 95, 2012.